International Health Management Associates, Inc. (IHMA) has been commissioned to conduct the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), a global in vitro surveillance study for tigecycline, a broad-spectrum antibiotic currently under investigation. The study will evaluate the activity of tigecycline against a variety of bacteria, including strains resistant to currently approved drugs, at approximately 690 hospitals in approximately 35 countries over the next three years. Tigecycline is an injectable glycylcycline, a new class of antibiotics, being developed by Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE).

"T.E.S.T. is likely one of the largest surveillance studies of its kind ever undertaken. The trial will evaluate the activity of tigecycline against a wide range of clinical pathogens collected from diverse patient populations worldwide. Almost all bacterial strains have developed some level of antibiotic resistance, so this study will enable us to document with in vitro laboratory data the activity of this new antibiotic against bacterial pathogens, including those exhibiting multiple antibiotic resistance," said Daryl Hoban, Ph.D., Director of Clinical and Laboratory Services.

About T.E.S.T.
T.E.S.T. investigators will collect and evaluate clinically significant isolates from a variety of infection sites. The isolates will be tested in vitro to evaluate the activity of tigecycline compared with currently available antimicrobial agents.

The T.E.S.T. data will build upon the drug's in vitro data collected in ongoing Phase 2 and Phase 3 clinical trials in patients. Phase 2 clinical trials investigated use of tigecycline to treat complicated skin and skin-structure or complicated intra-abdominal infections. Phase 3 clinical trials are nearing completion. Laboratory tests from clinical trials have examined tigecycline's activity against a broad spectrum of pathogens, including gram-positive, gram
'"/>

Contact: Jennifer Petra
jpetra@porternovelli.com
212-601-8110
Porter Novelli
19-May-2004

Page: 1 2
Related biology news :

1. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
2. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
3. Smart antibiotics may result from UCLA research
4. K-State researcher working to improve alternatives to equine antibiotics
5. Bacterial protein recycling factor possible key to new class of antibiotics
6. Bacteria spill their guts to aid researchers in quest for new antibiotics
7. Molecule that blocks key bacterial enzyme may lead to new antibiotics
8. Does antibiotic use contribute to allergies?
9. Data show investigational antibiotic safe, effective in preventing travelers diarrhea
10. Chicken litter harbors agents that generate antibiotic multi-resistance, according to UGA study
11. New York microbiologists awarded research grants in antibiotic resistance and lyme disease